Last reviewed · How we verify
COVAXIN
At a glance
| Generic name | COVAXIN |
|---|---|
| Sponsor | Tan Tock Seng Hospital |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC] (PHASE4)
- Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers
- Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults (PHASE2,PHASE3)
- BBV152/BBV154 Heterologus Prime-Boost Study (PHASE2)
- Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose (PHASE3)
- Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
- Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers (PHASE3)
- COVAXIN in a Pediatric Cohort (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVAXIN CI brief — competitive landscape report
- COVAXIN updates RSS · CI watch RSS
- Tan Tock Seng Hospital portfolio CI